Post
CNBC
cnbc.com
did:plc:m7ks2xhfuku7errrtfjux2lg
Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting analysts to slash peak sales forecasts and rethink the company’s obesity strategy.
Read more: cnb.cx/4xJ7hbG
2026-06-21T09:00:10.269Z